For citizens

For companies

For medical specialists

PRAC recommends restricted use for bromocriptine in inhibiting post-partum lactation

The PRAC has completed an EU-wide review of bromocriptine-containing medicines for preventing or suppressing lactation (breast milk production) in women after childbirth.

Because an association of such treatment with rare but potentially serious (including fatal) cardiovascular, neurological and psychiatric side effects cannot be ruled out, the PRAC has recommended that the medicines only be used for this purpose when there are compelling medical reasons for stopping lactation, such as to avoid further distress after loss of the baby during or just after childbirth, or in mothers with HIV infection, who should not breastfeed. Bromocriptine should not be used routinely for preventing or stopping milk production, nor to relieve symptoms of pain or swelling of the breasts after childbirth.

The Committee also concluded that bromocriptine must not be used in women at increased risk of serious side effects, including women with disorders that increase blood pressure or severe psychiatric disorders.

More information is available in the hyperlink below.

Bromocriptine-containing medicines indicated in the prevention or suppression of physiological lactation post-partum